Mylan Launches Generic Frova

The tablets are indicated to treat acute migraines in adult patients
The tablets are indicated to treat acute migraines in adult patients

Mylan announced the launch of Frovatriptan Succinate Tablets, the generic version of Endo's Frova.

Frova, a selective 5-HT1B/1D receptor agonist, is indicated to treat acute migraine headaches with or without aura in adult patients. It binds with high affinity to 5-HT1B/1D receptors. The therapeutic activity of frovatriptan is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. 

Related Articles

Frovatriptan Succinate Tablets are available as a 2.5mg strength. 

For more information call (800) RX-MYLAN or visit Mylan.com.

Loading links....